Chemotherapy in Addition to Supportive Care Improves Survival in Advanced Non–Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis of Individual Patient Data From 16 Randomized Controlled Trials
Top Cited Papers
- 1 October 2008
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 26 (28), 4617-4625
- https://doi.org/10.1200/jco.2008.17.7162
Abstract
Since our individual patient data (IPD) meta-analysis (MA) of supportive care and chemotherapy for non–small-cell lung cancer (NSCLC), published in 1995, many trials have been completed. An updated, IPD MA has been carried out to assess newer regimens and determine conclusively the effect of chemotherapy. Systematic searches for randomized controlled trials (RCTs) were undertaken, followed by central collection, checking, and reanalysis of updated IPD. Results from RCTs were combined to calculate individual and pooled hazard ratios (HRs). Data were obtained from 2,714 patients from 16 RCTs. There were 1,293 deaths among 1,399 patients assigned supportive care and chemotherapy and 1,240 among 1,315 assigned supportive care alone. Results showed a significant benefit of chemotherapy (HR, 0.77; 95% CI, 0.71 to 0.83; P ≤ .0001), equivalent to a relative increase in survival of 23% or an absolute improvement in survival of 9% at 12 months, increasing survival from 20% to 29%. There was no clear evidence that this effect was influenced by the drugs used (P = .63) or whether they were used as single agents or in combination (P = .40). Despite changes in patient demographics, the effect of chemotherapy in recent trials did not differ from those included previously (P = .77). There was no clear evidence of a difference or trend in the relative effect of chemotherapy across patient subgroups. This MA of chemotherapy in the supportive care setting demonstrates conclusively that chemotherapy improves overall survival in all patients with advanced NSCLC. Therefore, all patients who are fit enough and wish to receive chemotherapy should do so.This publication has 35 references indexed in Scilit:
- Addition of platinum compounds to a new agent in patients with advanced non-small-cell lung cancer: a literature based meta-analysis of randomised trialsAnnals of Oncology, 2004
- Chemotherapy versus supportive care in advanced non-small cell lung cancer: improved survival without detriment to quality of lifeThorax, 2004
- Measuring inconsistency in meta-analysesBMJ, 2003
- Quality of life and survival in patients with advanced non-small cell lung cancer receiving supportive care plus chemotherapy with carboplatin and etoposide or supportive care only. A multicentre randomised phase III trialEuropean Journal of Cancer, 1998
- Single agent versus combination chemotherapy in patients with advanced nonsmall cell lung carcinomaCancer, 1998
- Cisplatin-Cyclophosphamide-Mitomycin Combination Chemotherapy With Supportive Care Versus Supportive Care Alone for Treatment of Metastatic Non-Small-Cell Lung CancerJNCI Journal of the National Cancer Institute, 1993
- Lonidamine, chemotherapy (cisplatin and etoposide) and chemotherapy plus lonidamine vs the best supportive care in the treatment of advanced non small cell lung cancer (NSCLC). Preliminary results of a randomized studyLung Cancer, 1991
- Chemotherapy in advanced non-small cell lung cancer : Splinter TAW. Department of Medical Oncology, University Hospital Rotterdam/Dijkzigt, Dr Molewaterplein 40, 3015 GD Rotterdam. Eur J Cancer 1990;26:1093-9Lung Cancer, 1991
- Beta blockade during and after myocardial infarction: An overview of the randomized trialsProgress in Cardiovascular Diseases, 1985
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958